Abstract: Olfactory neuron cultures and methods of making and using the same are disclosed. The olfactory neuron cultures may be used to study oxidative stress-related disorders and diseases such as Alzheimer's disease. The olfactory neuron cultures may be used to screen candidate compounds for those which reduce, inhibit or prevent oxidative stress or damage. The compounds which reduce, inhibit or prevent oxidative stress or damage may be used to treat Alzheimer's disease and other oxidative stress-related disorders and diseases.

Abstract: Compositions comprising a pharmaceutically effective amount of a compound that impedes disruption of intact dense microspheres (DMS) by acting on DMS either to prevent disruption, or if disrupted, act on pre-disrupted DMS in such a way that, when the composition is administered to a test animal that has received an injection of DMS, it reduces the mean volume of tissue occupied by disrupted DMS, reduces the ratio of the number of inflammatory cells per DMS, or increases the ratio of the number of macrophages containing disrupted DMS per DMS, are useful for treating cerebral amyloidosis.

Abstract: Purified, host-specific, non-toxic, wide host range and virulent bacteriophage preparations that are effective in killing bacterial organisms in vivo are disclosed. Also disclosed are compositions containing these bacteriophages, methods of making the bacteriophage preparations and methods of treating bacterial infections using the compositions. Methods of treating bacterial infections using the compositions containing the bacteriophages in combination with conventional antibiotics also are disclosed.

Abstract: The invention relates to an antigen associated with Alzheimer's disease and to antibodies specific for said antigen. This invention further relates to methods for diagnosing Alzheimer's disease utilizing assays containing Alzheimer's associated antigen, antibodies specific for said antigen and samples from an individual suspected of having Alzheimer's disease.

Abstract: A method for detecting elevated levels of the middle isoform of .alpha.-2 haptoglobin, .alpha.-2FS haptoglobin in bodily fluids of subjects with Alzheimer's disease and schizophrenia as compared with the .alpha.-2FS haptoglobin level in normal subjects. Fibrinogen fragments corresponding to proteins 127 and 128 are also found in elevated levels in such subjects. Elevated levels of specific haptoglobin proteins serve as a diagnostic marker for Alzheimer's disease and Schizophrenia.

Abstract: The present invention is directed to a fluorescence polarization immunoassay for determining the phenylacetylglutamine (PAG) content in body fluids, to the various components needed for preparing and carrying out such an assay, and to the methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for preparing them. The assay is conducted by measuring the degree of polarization of plane polarized light that has been passed through a solution continuing sample, antiserum and tracer.

Abstract: The present invention is directed to a fluorescence polarization immunoassay for determining the phenylacetylglutamine (PAG) content in body fluids, to the various components needed for preparing and carrying out such an assay, and to the methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for preparing them. The assay is conducted by measuring the degree of polarization of plane polarized light that has been passed through a solution continuing sample, antiserum and tracer.